Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01)
Tsuyoshi Hayashi(National Hospital Organization Hokkaido Medical Center), Satoshi Hirano(Hokkaido University of Science), Eiichi Tanaka(Yamagata University), Katsutoshi Miura(Teine Keijinkai Hospital), Yoshiyasu Ambo(Hokkaido University of Science), Masanori Someya(Sapporo Medical University), Masayo Motoya(Sapporo Medical University), Yasutoshi Kimura(Sapporo Medical University), Yusuke Sakuhara(Hokkaido University), Hiroshi Kawakami(Hokkaido University Hospital), Katsuhiko Murakawa(Obihiro Kosei General Hospital), Akio Katanuma(Tokyo Medical and Dental University), Takumi Yamabuki(The University of Tokyo), Kuniyuki Takahashi(Teine Keijinkai Hospital), Makoto Yoshida(Harvard University), Hajime Yamazaki(Fukushima Medical University), Toru Nakamura(Hokkaido University), Norio Katoh(Hokkaido University)
International Journal of Radiation Oncology*Biology*Physics
July 12, 2019
Cited by 26
Related Papers
Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines
|Journal of Hepato-Biliary-Pancreatic Surgery|2007|489
Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer
|British journal of surgery|2018|401
Distal Pancreatectomy With En Bloc Celiac Axis Resection for Locally Advanced Pancreatic Body Cancer
|Annals of Surgery|2007|315
Clinical practice guidelines for the management of biliary tract cancers 2015: the 2<sup>nd</sup> English edition
|Journal of Hepato-Biliary-Pancreatic Sciences|2015|300